34 results about "Disease complication" patented technology

The invention discloses micro ribonucleic acids (microRNA, miRNA) carried by cell microparticles (Microparticle, MP), a method for preparing the same, and application thereof in the technical field of biotechnological pharmacy. The invention provides a combination of the micro ribonucleic acids for evaluating the physiological and / or pathological states of a participant, and the combination contains all the micro ribonucleic acids which exist stably in serum / plasma particles of the participant and are detectable. At the same time, the invention provides an experimental method for preparing the cell microparticles containing specific micro ribonucleic acids and using the cell microparticles to perform gene-level regulation and control as well as modification on other cells and tissues. The combination and the method can be used for detecting and treating various diseases, including the aspects of the diagnosis and the differential diagnosis of various tumors, various acute and chronic infectious diseases and other acute and chronic diseases, the prediction and the curative effect evaluation of the occurrences of disease complications and the recurrences of malignant diseases, as well as the active ingredient screening, the efficacy evaluation and the judicial authentication of drugs, the detection of prohibited drugs and the like; besides, the combination and the method have the advantages of wide detection pedigree, high sensitivity, low detection cost, convenient available material, easy storage of samples and the like.

The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and / or progression to surgery.

The invention relates to a marker for detecting colon and rectum cancer by utilizing 86 specific ribonucleic acids stably existing in the serum / plasma of a human body, as well as a method, a relevant kit and a biological chip for detecting the marker. The method can be used in the aspects of diagnosing and differentially diagnosing the colon and rectum cancer and predicting the generation and the recurrence of the complications of diseases, evaluating the curative effect, screening the active ingredients in drugs, evaluating the drug effect and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, material is convenient for obtainment, samples are easy to store and the like. The method can be widely used for generally surveying the colon and rectum cancer and relevant work and improving low specificity and low sensitivity which are brought by the individual difference difficultly and are difficult to overcome by the single marker, thereby obviously enhancing the clinical detection rate of the colon and rectum cancer and becoming an effective means for early diagnosing the colon and rectum cancer.

The invention provides a pancreatic cancer marker, and a detection method, a kit and a biochip thereof. The pancreatic cancer marker provided by the invention contains 36 kinds of micro ribonucleic acids which stably exist in the serum / plasma of a person receiving the test and can be detected. The invention also provides a kit and a biochip of tools or elements for detecting the pancreatic cancer marker. The combination, the method, the kit and the biochip provided by the invention can be used for auxiliary diagnosis and differential diagnosis of pancreatic cancers, predication of occurrence and recrudescence of disease complications, evaluation of the curative effect, screening of active ingredients of medicaments, evaluation of pesticide effectiveness and the like, and has the advantages of wide detection range, high sensitivity, low detection cost, readily available raw materials, easy storage of samples and the like; and the method is widely applied to work related to the general survey of pancreatic cancers, improves the specificity and sensitivity which are low in the single marker due to individual difference, obviously increases clinical detection rate of pancreatic cancers and becomes an effective method for early diagnosis of pancreatic cancers.

The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and / or progression to surgery.

The invention relates to a breast cancer detecting marker by utilizing 16 specific tiny ribonucleic acids steadily existing in blood serum and blood plasma of a human body as well as a detecting method, a kit and a biological chip thereof, and the detecting marker can be used in the aspects of diagnosis and differential diagnosis of breast cancer, occurrence and recurrence forecast as well as efficacy assessment of disease complications, screening and therapeutic evaluation of medicinal active ingredients and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, the materials are conveniently taken, the samples are easy to store and the like. The method can be widely used in related work such as breast cancer census, the defects of low specificity and low sensitivity caused by insuperable individual difference of a single marker can be improved and the clinical detectable rate of the breast cancer is notably improved, and is an effective mean of early breast cancer diagnosis.

The invention provides a method and device for evaluating the efficacy of a chronic disease drug. The method includes the steps of determining a clustering method; clustering real feature data of a case according to the clustering method, and obtaining drug use information and diagnostic information corresponding to different categories; and analyzing the efficacy of each drug according to the drug use information and diagnostic information corresponding to the different categories. The method provided by the invention can be applied to the theoretical research related to the evaluation of theefficacy of the chronic disease drug, and can also be applied to the prediction, early warning and drug recommendation of the clinical disease complications simultaneously. The analysis results are detailed, accurate, small in error. The larger the number of data samples is, the greater the credibility of the analysis results is. Great convenience is brought to medical workers in analyzing and judging the treatment of chronic diseases. The method is of great significance for the analysis of biological and medical related fields.

The invention relates to a gastric cancer detection marker, and a detecting method thereof, a related kit and a biochip. The gastric cancer detection marker comprises 21 specific micro RNAs stable in human serum / plasma. The marker which is broad in detection spectrum, high in sensitivity, low in detection cost, easy to be got and stored can be used for diagnosing and differentially diagnosing the gastric cancer, predicating occurrence and reoccurrence of diseases and conditions, evaluating therapeutic efficiency and efficacy and screening active pharmaceutical ingredients and the like. The method can be widely applied to cancer survey and related work, improves low specificity and low sensitivity caused by individual difference which is difficult for a single marker to overcome, and remarkably improves the clinical detection rate of the gastric cancer. Therefore, the method is an effective means to diagnose early breast cancer.

The invention provides the combination of microRNAs used for evaluating the liver cancer condition of a subject and contains microRNAs which exist stably and are detectable in the serum / plasma of the subject. A method for evaluating the liver cancer condition of the subject comprises a step of measuring the microRNAs which exist stably and are detectable in the serum / plasma of the subject. A kit used for evaluating the liver cancer condition of the subject contains a tool for measuring the microRNAs which exist stably and are detectable in the serum / plasma of the subject. A biochip for evaluating the liver cancer condition of the subject contains a component for measuring the microRNAs which exist stably and are detectable in the serum / plasma of the subject. The novel technology can be used in the aspects of the diagnosis and the differential diagnosis, the prognosis of the generation and the recurrence of the disease complication and the therapeutic effect evaluation of liver cancer, the screening and the pharmacological effect evaluation of medicinal active ingredients and the like.

The invention relates to 17 specific micro ribonucleic acids serving as cervical cancer detection markers, existing in human serum / plasma and capable of being detected, and a method, a related kit and a biochip for detecting the markers. The markers can be used for diagnosis and identification of cervical cancer, prediction of occurrence and relapse of disease complications, curative effect evaluation, screening of medicinal active ingredients, medicinal effect evaluation and the like, have the advantages of broad detection spectrum, high sensitivity, low detection cost, convenience for taking materials and the like, and are easy to store samples. The method can be widely used for related operations such as cervical cancer general investigation and the like, improves low specificity and low sensitivity caused by individual difference difficult to be overcome by single marker, remarkably improves the clinical detection rate of the cervical cancer, and becomes an effective means for early diagnosing the cervical cancer.

The invention relates to agents for sequestering serum aging factors, and methods for using the same. More particularly, the invention relates to agents termed herein 'Naractin' to denote any one of several naturally-occurring arNOX inhibitors either present in N. tazetta powder or capable of augmenting N. tazetta powder to an inhibitory level comparable to that of the fresh N. tazetta extracts, and to methods for using 'Naractins' to prevent or treat disorders and complications of disorders resulting from cell damage caused by an aging-related isoform of NADH oxidase (arNOX). In one exemplary embodiment the agents of the invention comprise at least one naturally occurring Naractin. Such naturally occurring naratins are also capable of augmenting the anti-arNOX effect of other naturally occurring arNOX inhibitory agents.

The invention relates a medicinal composition containing Gliquidone, taurine and its medicinal salts, and the use of the composition in preparing medicament for the treatment of diabetes, the treatment and / or prevention of renal disease complication related to type II diabetes. The composition comprises Gliquidone 10-180mg, taurine and its medicinal salts 0.5-10g, and pharmaceutically acceptable carrying agents.

The invention relates to a TCM (traditional Chinese medicine) preparation for treating porcine circovirus disease and belongs to the technical field of TCM preparations for treating porcine circovirus disease complications. The TCM preparation is prepared with the monarch drugs, including gypsum, common anemarrhena rhizome, weeping Forsythiae capsule, rhizome of rehmannia and root bark of the peony tree; the adjuvant drugs, including light yellow Sophora root, dittany bark, Amur cork tree bark and Akebia stem; the envoy drugs, including Chinese angelica and sesame seed; and the harmonizing drug, liquorice root. Based on the study and treatment rules in traditional Chinese medicine, the TCM preparation composed according to the TCM theory has the effects of removing heat to cool blood, promoting blood circulation to remove blood stasis, expelling wind to resolve the exterior, and dispelling wind and eliminating dampness; thus the TCM preparation helps improve the body immunity and resistance in pigs and effectively inhibit or kill the porcine circovirus to cure the porcine circovirus disease.

The invention discloses a multifunctional rehabilitation bed which comprises a bed board, a backrest, a hanger and bed legs. A group of parallel sliding grooves are formed in each lateral side of the bed board, one end of each sliding groove is connected with a first supporting rod through a fixing member, a pedal is arranged at one end of each first supporting rod, the other end of each sliding groove is connected with a second supporting rod through a fixing member, a pull ring is arranged at one end of each second supporting rod, a lifting plate is arranged in the middle of the bed board, one end of the lifting plate is connected with the supporting rods through springs at the bottom while the other end of the same is connected with the bed board through a connecting member, a button is arranged on one side of the backrest, the hanger is provided with a hook and an LED lamp, and the bottom of the bed board is connected with a tabletop through a connecting rod. The multifunctional rehabilitation bed has the advantages that on the basis that the multifunctional rehabilitation bed has functions of a common sickbed, a component with multiple rehabilitation structures is added, so that a patient can conduct related rehabilitation training on the bed; disease complications caused by the fact that the patient is bedridden can be reduced.

The invention belongs to the field of medicines, and particularly relates to application of nitazoxanide in preparation of a medicine for preventing and treating interstitial lung diseases. Accordingto the application of nitazoxanide in preparing the medicine for preventing and treating interstitial lung diseases, further, nitazoxanide is nitazoxanide and an in-vivo active metabolite of nitazoxanide. The interstitial lung diseases comprise disease complications caused by coronavirus infection. According to the invention, detailed research is carried out on the improvement of the interstitiallung disease by the nitazoxanide, the variety of medicines for treating the interstitial lung diseases is expanded, and the new application of nitazoxanide is also expanded.

The invention discloses a molecular marker for early pancreatic neoplasm detection as well as a detection method and application thereof and belongs to the field of biotechnology and clinical molecular diagnosis drug development. A pancreatic cancer marker miRNAs includes miR-30c, miR-24, miR-23a and miR-132. Combination, a method and a kit provided by the invention can be used for evaluation on aspects of screening and identifying diagnostics of early pancreatic cancer, monitoring of disease complications and recurrence, curative efficacy, efficacy, accurate medication guidance and the like and have the advantages of wide detection lineage range, high sensitivity, good specificity, low detection cost, availibility in material, easies in storage of samples and the like. The method can be widely used for related work such as early survey and prognosis of pancreatic cancer, improves individual differences difficult to overcome as well as low specificity and low sensitivity brought by theinstability of a single marker or a biomarker which is clinically widely applied self at present, significantly increases the clinical detection rate of the early pancreatic cancer, lowers the misdiagnosis rate and the missed diagnosis rate of the pancreatic cancer and becomes effective means of screening and diagnosis of the early pancreatic cancer.

The invention provides an application of a compound as shown in the formula A to preparation of a medicine for restraining clostridium difficile thalli and / or restraining germination of clostridium difficile spores. R1 and R2 are independently selected from C1-3 alkyl group, C2-3 alkenyl and C2-3 alkynyl. Experiment proves that the compound as shown in the formula A, particularly magnolol and honokiol can notably restrain activity of clostridium difficile, can notably restrain germination of clostridium difficile spores, and has good application prospects for preparation of the medicine for preventing and / or treating clostridium difficile infection diseases, recurrence of clostridium difficile infection diseases, and complications of clostridium difficile infection diseases.

The invention discloses novel traditional Chinese medicinal oral liquid for clearing away heat and toxic materials. The traditional Chinese medicinal oral liquid consists of the following raw material components in percentage by mass: 5-10% of chlorogenic acid, 6-8% of forsythin, 2-3% of dementholized peppermint oil, 1-3% of schizonepetoside, 3-4% of lycium barbarum polysaccharide, 2-3% of momordica glycosides, 2-3% of dried powder of platycodon root, 3-5% of glycyrrhizin and 61-76% of a glucose solution. The chlorogenic acid is extracted from honeysuckle flowers; and the glucose solution contains 5-8% of glucose. The novel traditional Chinese medicinal oral liquid for clearing away heat and toxic materials provided by the invention, compared with the prior art, has the following technical effects: (1) the traditional Chinese medicinal oral liquid, which is prepared from natural plant extracts, is free from toxic and side effects to human bodies; can (2) the traditional Chinese medicinal oral liquid, which is prepared from high-purity plant extracts, is better in taste than conventional medicinal pills and capsules and convenient to take; and the traditional Chinese medicinal oral liquid not only can be used for clearing away heat and toxic materials for disease complications, but also can serve as an excellent drink for relieving summer heat in midsummer.

A computer-implemented method of facilitating physiological property forecasting for detecting disease complications is disclosed. The method involves receiving signals representing sensed physiological property indicators, each of the sensed physiological property indicators representing a sensed physiological property of a patient at a respective time and receiving signals representing one or more contextual indicators associated with the sensed physiological property indicators. The method also involves applying at least one classification criterion to the one or more contextual indicators to determine a patient state of a plurality of possible patient states, each patient state associated with a respective set of forecasting parameters and applying the set of forecasting parameters associated with the determined patient state to the sensed physiological property indicators to determine at least one forecast physiological property indicator representing a forecast physiological property of the patient at a future time. Other methods, systems and computer-readable media are also disclosed.

The invention discloses a neurodegenerative disease diagnosis-and-treatment system based on big data and VR technology, wherein the system relates to the field of virtual reality technology. The system settles a problem of high difficulty in diagnosis-and-treatment operation of a neurological disease caused by patient individual differences, changeable conditions, multiple obstacles of neurological disease complications in diagnosis-and-treatment of the neurological disease. The system is technologically characterized in that the system comprises a modeling system and a VR operating system; the modeling system comprises a data acquisition unit, a big data modeling unit and a pathological simulating unit; the big data modeling unit is connected with the data acquisition unit; the pathological simulating unit is connected with the data acquisition unit, the big data modeling unit and the VR operating system; and the VR operating system comprises a complication setting unit, a visual feedback unit and a tactile feedback unit. The neurodegenerative disease diagnosis-and-treatment system has advantages of supplying a neurodegenerative disease patient treatment-and-diagnosis drilling system to a neurology department doctor, performing diagnosis-and-treatment training on the neurology department doctor and improving treatment-and-diagnosis accuracy of the neurodegenerative disease by the neurology department doctor.

The present invention is directed to use of a series of tri-aryl compounds and compositions comprising the same for the treatment of diabetes and disease conditions arising as a consequence of the same.

The invention provides an asthenospermia marker as well as a detection method and a kit thereof. The asthenospermia marker provided by the invention comprises ribonucleic acid piR-57660 which stably exists in seminal plasma of a subject, can be detected and interacts with Piwi protein. The invention also provides a kit comprising a tool or element for detecting the asthenospermia marker. The combination, the method and the kit provided by the invention can be used for assisting in diagnosis and differential diagnosis of asthenospermia, prediction of occurrence and relapse of disease complications, curative effect evaluation, screening of active pharmaceutical ingredients, drug effect evaluation and the like, and have the advantages of high sensitivity, low detection cost, convenience in material taking, easiness in sample storage and the like; the method can be widely applied to general survey of asthenospermia and other related work, and becomes an effective means for early diagnosis of asthenospermia.

The present invention is directed to use of a series of tri-aryl compounds and compositions comprising the same for the treatment of diabetes and disease conditions arising as a consequence of the same.

The subject matter described herein generally relates to a computing system that can receive values of a plurality of biomarkers from a user, generate a score for each biomarker, compute a severity associated with each biomarker, generate an overall score for the user based on at least one of the score for each biomarker and the severity associated with each biomarker, generate treatment recommendations based on the score for each biomarker and the severity associated with each biomarker, and send those treatment recommendations to the user. The treatment recommendations can: 1) prevent or reduce disease progression within the user and the development of disease complications within the user, 2) reverse the disease or its complications within the user, and / or 3) reduce the need for medications the user is already taking for his / her condition. Related methods, techniques, systems, apparatuses, and articles are also described.

The invention provides a method and device for evaluating curative effect of chronic disease medicine. Wherein, the method includes: determining a clustering method; clustering the real characteristic data of the case according to the clustering method to obtain medication information and diagnosis information corresponding to different categories; according to the medication information and diagnosis information corresponding to different categories The information analyzes the efficacy of each drug. The method provided by the present invention can not only be applied to theoretical research related to the evaluation of chronic disease drug effects, but also can be applied to the prediction, early warning and medication recommendation of clinical disease complications at the same time. The analysis results are detailed, accurate, and the error is small. The larger the analysis results, the higher the reliability, which brings great convenience to medical workers in analyzing and judging the treatment plan of patients with chronic diseases, and is of great significance to the analysis of biology and medical related fields.

The invention relates to a gastric cancer detection marker, and a detecting method thereof, a related kit and a biochip. The gastric cancer detection marker comprises 21 specific micro RNAs stable in human serum / plasma. The marker which is broad in detection spectrum, high in sensitivity, low in detection cost, easy to be got and stored can be used for diagnosing and differentially diagnosing the gastric cancer, predicating occurrence and reoccurrence of diseases and conditions, evaluating therapeutic efficiency and efficacy and screening active pharmaceutical ingredients and the like. The method can be widely applied to cancer survey and related work, improves low specificity and low sensitivity caused by individual difference which is difficult for a single marker to overcome, and remarkably improves the clinical detection rate of the gastric cancer. Therefore, the method is an effective means to diagnose early breast cancer.